
Amgen enlists TCR startup TScan to work on Crohn's in deal potentially worth $500M+
Amgen is taking a closer look at using T cells for inflammation, announcing a new deal Tuesday with TCR upstart TScan Therapeutics.
The companies will team up to discover new targets for Crohn’s disease, and Amgen has the option to expand the agreement into ulcerative colitis. Amgen is paying $30 million upfront to use TScan’s platform for examining how T cells interact with antigens in Crohn’s, and is promising more than $500 million in biobucks as well as single-digit royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.